Open an account

Longeveron

LGVN · NASDAQ

$1.50+$0.11 (+7.91%)TodayMarket closed ·
Prev close $1.39

About LGVN

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 26 full-time employees. The company went IPO on 2021-02-12. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The firm is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Employees
26
Headquarters
Miami, Florida
Listed
Feb 12, 2021
Sector
Health Care
Industry
Biotechnology
Website
longeveron.com

LGVN key statistics

Market cap
4.78M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
87.11K
Volume
50.62K
Open price
$1.40
High today
$1.52
Low today
$1.36
52 Week high
$12.30
52 Week low
$1.31

Longeveron (LGVN) at a glance

Longeveron (LGVN) last traded at $1.50, with a market cap of 4.78M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.36 and $1.52. The current price is 10.3% above the day's low and 1.3% below its high.

Volume so far is 50.62K shares, below the average of 87.11K shares a day.

Over the past year Longeveron has ranged from $1.31 to $12.30, and now sits 2% of the way up that range.

Longeveron met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.90 per share against an estimate of -$1.78.

The average analyst price target is $42.97, 2764.5% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $42.97
Low
$4.29
Now
$1.50
High
$84.00

LGVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 26.2% on average.

  1. Q3 FY24: reported -$3.40 per share against an estimate of -$4.52
  2. Q4 FY24: reported -$4.30 per share against an estimate of -$3.47
  3. Q1 FY25: reported -$3.40 per share against an estimate of -$3.34
  4. Q2 FY25: reported -$3.30 per share against an estimate of -$3.60
  5. Q3 FY25: reported -$3.90 per share against an estimate of -$2.60
  6. Q4 FY25: reported -$2.30 per share against an estimate of -$4.23
  7. Q1 FY26: reported -$1.90 per share against an estimate of -$1.68
  8. Q2 FY26: reported -$1.90 per share against an estimate of -$1.78

LGVN news

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Tanya Rawat

    Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why

  • Rishabh Mishra

    Stock Market Today: Dow Jones, S&P 500, Nasdaq 1000 Futures Advance as Scott Bessent Expands Sanctions on Iran—NTS, GRRR, REAX, ZM, LGVN in Focus (UPDATED)

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releaseGlobe Newswire

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Similar companies

Companies in the same industry as Longeveron

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.